R&D channel feed – Endpoints News

R&D channel feed

Rivus details weight loss data in heart failure patients and preps for new fundraise

7 months ago

Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

7 months ago

Updated: Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

7 months ago

Cereno Scientific details mid-stage results for pulmonary arterial hypertension drug

7 months ago

For some multiple myeloma patients, Carvykti cut risk of death by 45%

7 months ago

Travere halts Phase 3 inherited disease trial due to manufacturing scale-up issue

7 months ago

Endpoints 11 winner Xaira Therapeutics: Biotech’s largest AI bet with A-list backers

7 months ago

Genentech's Gazyva hits primary endpoint in late-stage kidney disease trial

7 months ago

A Parkinson's drug that AbbVie acquired from Cerevel succeeds in another Phase 3

7 months ago

Biogen walks away from Sage's essential tremor drug after mid-stage flop, pill's future in question

7 months ago

EnGene unveils first set of pivotal data for NMIBC therapy

7 months ago

Exclusive: J&J folds cardiovascular and metabolic drug unit

7 months ago

Celldex reveals Phase 2 responses for chronic hives drug and higher rates of neutropenia

7 months ago

Novo's semaglutide shows potential in chronic skin condition in obese patients

7 months ago

Merck's LAG-3 plus Keytruda combo fails Phase 3 in colorectal cancer

7 months ago

2seventy bio, Bristol Myers stop late-stage Abecma study in multiple myeloma due to recruitment challenges

7 months ago

Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis

7 months ago

Wave rides new Phase 2 DMD data as it sets sights on accelerated approval

7 months ago

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

7 months ago

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

7 months ago

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

7 months ago

Corrected: Over a year after FDA rejection, Biohaven claims success in pivotal neurodegenerative disease study

7 months ago

Black Diamond treads water on small snapshot of Phase 2 lung cancer data

7 months ago

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

7 months ago

First page Previous page 23 24 252627 28 29 Next page Last page